CardioExchange Archive

September 18th, 2013

Is Edoxaban the Most Promising of the Novel Anticoagulants?

Samuel Goldhaber, MD

Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.

---

September 1st, 2013

Positive Results for Edoxaban in VTE/PE

Larry Husten, PHD

Findings from the Hokusai-VTE trial of edoxaban

---

July 8th, 2013

Selections from Richard Lehman’s Literature Review: July 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a home-based walking intervention for those with PAD, BNP screening and collaborative care for HF, clopidogrel with aspirin in acute minor stroke or transient ischemic attack, and more.

---

July 1st, 2013

New Anticoagulant Found Safe and Effective in Acute Venous Thromboembolism

Larry Husten, PHD

In a large clinical trial the new oral anticoagulant apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was at least as effective as standard therapy and caused fewer bleeding complications in patients with acute venous thromboembolism (VTE). The results of the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial are being presented today at […]

---

March 26th, 2013

Should the Use of IVC Filters be Filtered Until We Have More Data?

Behnood Bikdeli, M.D.

There’s been a remarkable increase in the use of IVC filters, but what is the evidence base behind this mechanistically appealing approach?

---

March 22nd, 2013

Macrolide Antibiotic Linked to Increased CV Risk in Patients with Lung Conditions

Nicholas Downing, MD

Use of the macrolide clarithromycin in patients admitted with exacerbations of chronic obstructive pulmonary disease or community-acquired pneumonia is associated with increased risk for cardiovascular events, a BMJ study finds. Researchers examined outcomes among nearly 3000 patients admitted to U.K. hospitals with either condition. During 1 year of follow-up, there were roughly 450 new admissions for […]

---

February 25th, 2013

Selections from Richard Lehman’s Literature Review: February 25th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.

---

December 12th, 2012

AMPLIFYING Treatment for DVT/PE

John Ryan, MD

John Ryan reviews the latest data and suggests that DVT/PE be managed as a chronic condition. Are you using apixaban in these patients, and how long are you treating them for?

---

December 8th, 2012

Prolonged Anticoagulation with Apixaban Beneficial in Venous Thromboembolism

Larry Husten, PHD

A new study suggests that extending anticoagulant therapy for an additional year may be beneficial after patients with venous thromboembolism complete their initial course of therapy. The results of AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) were presented at the annual meeting of the American Society […]

---

October 29th, 2012

Selections from Richard Lehman’s Literature Review: October 29th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include CV risk factors and peripheral artery disease in men, radiofrequency ablation in paroxysmal AF, CPR duration and survival after in-hospital cardiac arrest, an everolimus-eluting stent vs. a bare-metal stent in STEMI, job strain and CHD, and more.

---